Peter Lynch fit · Growth at a reasonable price (GARP)
Is Xeris Biopharma Holdings, Inc. Common Stock (XERS) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria — growth too low or price too high.
22/100
FNão encaixa
2/6 critérios atendidos
Os critérios de Peter Lynch, aplicados a XERS
PEG ≤ 1.0
chave—
EPS CAGR ≥ 15%
chave0.0%
Revenue CAGR ≥ 10%
24.1%
Net margin > 0
-5.9%
Como XERS pontua em outras estratégias
Dados financeiros ao vivo
Cap. de mercado
$1.07B
P/L (TTM)
92.7x
ROIC (TTM)
12.84%
Margem bruta
81.59%
Outras análises Peter Lynch
Perguntas frequentes
What is XERS's Peter Lynch fit score?
XERS scores 22/100 on our Peter Lynch fit engine — grade F. Does not fit Lynch's GARP criteria — growth too low or price too high.
Does Peter Lynch actually own XERS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends XERS.
How often is this score updated?
XERS's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Ferramenta educacional, não é consultoria de investimento. As pontuações são calculadas a partir de dados financeiros públicos contra os critérios publicados de cada estratégia de investimento. Não afirmamos que Peter Lynch possua ou recomende XERS pessoalmente.